# Q-Line Biotech 的首次公開募股認購達 3.82 倍。

*biotech · news · 2026-05-21 · Moneycontrol*

## Key points

- Q-Line Biotech 的首次公開募股首日認購達 3.82 倍，主要由非機構投資者領銜。
- Q-Line 在首次公開募股開始前，從包括 HDFC Bank 和 Abakkus 在內的 18 位基石投資者籌得 61.09 億盧比。
- Bio Medica Laboratories 的首次公開募股首日認購率僅為 68%，認購不足。
- 儘管散戶需求疲弱，Bio Medica 的合格機構買家部分仍超額認購 15.94 倍。
- Bio Medica 籌資 52.4 億盧比，資金主要用於償還貸款及擴充設施。

Carnelian Asset Advisors founder Vikas Vijaykumar Khemani-backed Q-Line Biotech's IPO saw a healthy subscription of 3.82 times but Bio Medica Laboratories public issue was undersubscribed on May 21, their first day of bidding. Both offers will remain open till May 25. Diagnostic equipment and IVD products maker Q-Line Biotech approached capital markets to raise Rs 214.5 crore via initial public offering (IPO) of 62.53 lakh shares at the upper end of price band of Rs 326-343 per share. It attracted bids for 1.7 crore equity shares against the offer size of 44.72 lakh shares via 11,267 applications, thanks to the demand from across categories of investors. Non-institutional investors were at the leading position to boost Q-Line IPO's subscription numbers, bidding 5.2 times their allotted quota, while the portions set aside for qualified institutional buyers and retail investors were subscribed 4.14 times and 3.6 times, respectively. On May 20, a day before the IPO opening for public, Q-Line Biotech has already raised Rs 61.09 crore by issuing 17.81 lakh shares to 18 anchor investors including Abakkus, Carnelian AIF, Bharat Venture Opportunities Fund, Tiger Strategies Fund, Finavenue Capital, HDFC Bank, 360 ONE, and Tattvam AIF Trust. The company will spend its IPO proceeds mainly for its working capital requirements, and repayment of certain borrowings. And the remaining funds will be utilised for general corporate purpose. Click Here To Read All IPO News Q-Line Biotech supplies diagnostic equipment and IVD (in-vitro diagnostics) products since 2013 directly or through distributors majorly to diagnostic service providers, hospitals and medical colleges. Meanwhile, the initial public offering of Bio Medica Laboratories was subscribed at 68 percent with investors picking up 25.82 lakh shares against offer size of 37.72 lakh shares via 997 applications. Qualified institutional buyers' reserved portion saw 15.94 times subscription, while the parts set aside for non-institutional and retail investors were booked 2 percent and 1.09 times, respectively. The pharmaceutical parenteral formulations manufacturer is raising Rs 52.4 crore via IPO which comprises of fresh issuance of 33.95 lakh shares worth Rs 47.19 crore, and an offer-for-sale of 3.77 lakh shares worth Rs 5.24 crore by promoters. The proceeds from fresh issue will be utilised mainly for repayment of loan, and enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises. And the remainder funds will be kept aside for general corporate purposes. Bio Medica Laboratories that manufactures generic drugs in the form of injectables - liquid injections and dry powder injections - is valued at Rs 174.8 crore at the upper end of price band of Rs 132-139 per share.

**Companies:** Q-Line Biotech, Bio Medica Laboratories

[Read the full story on Moneycontrol](https://www.moneycontrol.com/news/business/ipo/q-line-biotech-ipo-sees-healthy-subscription-but-bio-medica-labs-public-issue-undersubscribed-on-day-1-13926844.html)

---

Canonical: https://newsio.io/zh-TW/n/e151bb4c-ecb9-4360-927d-9109e2684b33/q-line-biotech-3-82-bio-medica-laboratories-5-21-5-25
Summarized by Newsio from Moneycontrol. https://newsio.io/how-it-works